Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307885 | 0.85 | TRPV1 (0.53) | CSNK2A2CSNK2A1TRPV1ADORA2BPTGS2 | |
| SCHEMBL306815 | 0.84 | CSNK2A2 (0.44) | CSNK2A2CSNK2A1TRPV1ADORA2BPTGS2 | |
| Hydrochloric Acid SCHEMBL308173 | 0.82 | CSNK2A2 (0.43) | CSNK2A2CSNK2A1TRPV1ADORA2BPTGS2 | |
| SCHEMBL306565 | 0.79 | PTGS2 (0.48) | CSNK2A2CSNK2A1ADORA2BPTGS2EGLN3 | |
| SCHEMBL307323 | 0.79 | DPP4 (0.52) | CSNK2A2CSNK2A1TRPV1ADORA2BDPP4 | |
| SCHEMBL308328 | 0.76 | PTGS2 (0.48) | CSNK2A2CSNK2A1TRPV1ADORA2BPTGS2 | |
| SCHEMBL4975758 | 0.74 | HDAC6 (0.53) | CSNK2A2CSNK2A1ADORA2BPTGS2HDAC6 | |
| SCHEMBL3038500 | 0.73 | CSNK2A2 (0.53) | CSNK2A2CSNK2A1ADORA2BPTGS2HDAC6 | |
| SCHEMBL5133267 | 0.72 | TRPV1 (0.55) | TRPV1POLBLMNAKDM4EALDH1A1 | |
| SCHEMBL14291770 | 0.71 | PTGS2 (0.49) | CSNK2A2CSNK2A1ADORA2BPTGS2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| EP-2051967-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | AstraZeneca AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | CSNK2A2 496/4885CSNK2A1 559/4885TRPV1 10/4885 |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | OPRD1, OPRK1, SDHA | CSNK2A2 712/4885CSNK2A1 816/4885TRPV1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.